| Zurich Market Talk - 08-02-2012 |
| 08.02.12 07:04 | |
|
Roche (SIX: RO, ROG) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application for pertuzumab and granted Priority Review. Link: Click Here Roche (SIX: RO, ROG) released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has recommended that shareholders not tender their shares to Roche. Link: Click Here Comet Group full year 2011: Sales at prior-year level, net income above expectations. Sales of CHF 217 million as in prior year, representing currency-adjusted growth of 12%. EBITDA margin of 12.6% slightly below prior year. Significant year-over-year growth expected in net income, to about CHF 10 million. Link: Click Here Syngenta: Sales increased by 12 percent at constant exchange rates (CER). Sales volume increased by 11 percent and prices were up one percent. Currency added a further two percent to give growth in reported sales of 14 percent. Link: Click Here Syngenta announced today that the Board of Directors will propose the election of three new members at the Annual General Meeting on April 24, 2012. On the same date two existing members of the Board, Pierre Landolt and Rolf Watter, will retire, having completed their term of office. Link: Click Here u-blox, the Swiss positioning and wireless chip and module company, has been chosen as the GPS technology provider for Grace Industries, a manufacturer of mission-critical personal safety devices. Grace’s latest intrinsically-safe personal tracker, the SuperCell® SC500-GPS, relies on u-blox 6 GPS technology to report critical location data of remote workers. Link: Click Here Novartis: The Journal of the American Medical Association (JAMA) published a study today that shows Bexsero induced a robust immune response against meningococcal B disease in the vast majority of infants vaccinated. These results also show that Bexsero can fit into various vaccination schedules in the first year of life when the likelihood of contracting this often-deadly disease is greatest. The study also demonstrated that Bexsero has an acceptable tolerability profile. Link: Click Here BKW Group has finalised decisions on the personnel and organisational measures to be implemented as part of the cost reduction programme announced in December 2011. The workforce will reduced in phases by around 255 jobs and across all divisions and subsidiaries, wherever possible through natural fluctuation and early retirement options. Link: Click Here Economy ******* German industrial production very weak in December. Industrial production fell by 2.9% (m/m) in December, much worse than expected (Barcap: 0.2%; Consensus 0.0%), even once taking into account the upward revision of the November figure to 0.0% from -0.6% previously announced. As a result, the average level of industrial production in Q4 was about 2 percent below its Q3 level. Link: Click Here Sarasin: A new world order calls for sustainable investment policies. A new world order is emerging. It is a powerful development that will be full of surprises – some profoundly positive, others stunningly negative. In the current issue of "Perspectives", Burkhard P. Varnholt, Chief Investment Officer of Bank Sarasin & Co. Ltd examines the non-linear, interconnected forces – economic, political, demographic and scientific – that together pose the greatest historical theme of our time. Link: Click Here |
| < Prev | Next > |
|---|